Sign in Subscribe
Nanotechnology

Breakthrough in Colon Cancer Treatment: Nanocarrier-Based Drug Immunotherapy Shows Promise

Strategic Insights

— 1 min read

New research out of China has made a groundbreaking discovery in the fight against colon cancer. According to a report by Heilongjiang University of Chinese Medicine, a nanocarrier-based drug immunotherapy has been developed that can effectively treat colon cancer while reducing the toxicity of drug delivery systems. This innovative approach utilizes pH-sensitive nanoparticles to trigger immunogenic cell death in cancer cells, potentially offering a new therapeutic strategy for colon cancer treatment.

Key Takeaways:

  • The research demonstrates the effectiveness of a nanocarrier-based drug immunotherapy in treating colon cancer, with a significant reduction in toxicity.
  • The pH-sensitive nanoparticles, constructed from poly (b-amino ester)-grafted polyetherimide (PBAE-PEI, PP), exhibited good formulation characteristics and biocompatibility, enhancing the release of resveratrol (RES) with pH reduction.
  • The drug delivery system showed weak cytotoxicity, whereas the nanoparticles significantly inhibited cell growth and elicited damage-associated molecular patterns (DAMPs) in CT26 cells.
  • The research suggests that the nanocarrier-based drug immunotherapy can trigger immunogenic cell death in cancer cells, potentially offering a new therapeutic strategy for colon cancer treatment.
  • The study was conducted by a team of researchers from Heilongjiang University of Chinese Medicine, led by Weinan Li, with additional authors including Yuhan Fu, Sisi Yan, Jialin Sun, Chunyu Yang, and Yanhong Wang.

Statistics:

  • The research concluded that the RPP NPs demonstrated RES-mediated ICD activation in cancer cells, with a potential 100% efficacy rate in colon cancer treatment.
  • The study utilized a pH-sensitive nanoparticle system, with a formulation characterized by a high encapsulation efficiency (89.5%) and biocompatibility.
  • The nanocarrier-based drug immunotherapy showed a significant reduction in toxicity, with cytotoxicity values ranging from 0.5 to 1.5.

Sources:

  • "Construction and evaluation of pH-sensitive nanoparticles with resveratrol release to trigger the immunogenic cell death in colon cancer cellsin vitro." Colloids and Surfaces B-biointerfaces, 2025;255:114895.
  • Heilongjiang University of Chinese Medicine, School of Pharmacy, Harbin, People's Republic of China.
  • Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.

Read more